Cogent Biosciences: Massive Upside Potential!
Cogent Biosciences, Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company targeting underlying causes of genetic dysfunction that cause diseases such as cancers, autoimmune disorders and rare diseases. The Company’s lead candidate bezuclastinib (CGT9486), is a precision kinase inhibitor that inhibits the KIT D816V mutation, which...
